PMX 205 Trifluoroacetate
Based on 14 publication(s) in Google Scholar
PMX 205 Trifluoroacetate is a specific complement C5aR1 isoform antagonist.
For research use only. We do not sell to patients.
- Purity: 99.50%
- Formula: C47H63F3N10O8
- Molecular Weight:953.06
-
Storage:
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocol
- Purity & Documentation
- References
-
Help & FAQs
-
Immunology/Inflammation Compound Library
HY-L007
-
Macrocyclic Compound Library
HY-L041
-
Heterocyclic Compound Library
HY-L138
-
Autoimmune Disease Compound Library
HY-L156
-
Highly Selective Inhibitors Library
HY-L158
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) PMX 205 Trifluoroacetate
More- Nature. 2025 Sep;645(8082):1051-1059. [Abstract]
- Theranostics. 2019 Oct 12;9(25):7566-7582. [Abstract]
- J Clin Invest. 2026 Feb 10:e199706. [Abstract]
- Adv Sci (Weinh). 2024 Jun 5:e2400819. [Abstract]
- Cell Death Dis. 2024 Oct 5;15(10):729. [Abstract]
- Nephrol Dial Transplant. 2026 May 13:gfag109. [Abstract]
- Cell Rep. 2023 Mar 15;42(3):112240. [Abstract]
- Cell Mol Neurobiol. 2023 Jul;43(5):1957-1974. [Abstract]
- Mol Neurobiol. 2025 Jul 10. [Abstract]
- Int J Cancer. 2023 Jul 1;153(1):224-237. [Abstract]
- Clin Immunol. 2025 Apr:273:110459. [Abstract]
- bioRxiv. 2026 Jun 16.
- bioRxiv. 2025 Aug 28:2025.08.22.671883. [Abstract]
- La Trobe University. 2022 Jan.
Customer Validation & Images
-
IF
-
WB
-
RT-PCR
-
Cell Proliferation/Viability Assay
-
WB
Biological Activity
C5aR[1]
A complement activation product, C5a, is known to recruit and activate microglia and astrocytes in vitro by activation of a G protein-coupled cell-surface C5aR. In the MTT assay, in 24 h plate, it shows that all groups are significant when compared with negative control group. For PMX 205 (PMX205) group, the value recorded is in between 0.09893 to 0.2465, EP54 group, 0.02724 to 0.1748 and Tamoxifen group, the value recorded in between 0.09880 to 0.2464. For the 48 h plate of incubation time, only two groups show a significant result, which are PMX 205 and Tamoxifen. The values recorded are in between 0.04987 to 0.3273 and 0.5777 to 0.8551 respectively. For the 72 h plate, only one group shows a significant result, PMX 205 (antagonist group) with the value recorded in between 0.02136 to 0.5322[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
Appearance Solid
-
Molecular Weight 953.06
-
Formula C47H63F3N10O8
-
Color White to off-white
-
SMILES
OC(C(F)(F)F)=O.O=C([C@H](NC([C@@]1([H])N(CCC1)C([C@](NC(CCC2=CC=CC=C2)=O)([H])CCCNC([C@H](CCCNC(N)=N)NC3=O)=O)=O)=O)CC4CCCCC4)N[C@@]3([H])CC5=CNC6=CC=CC=C56
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (14)
-
Journal Impact Factor
-
Most Recent
-
Nature
2025 Sep;645(8082):1051-1059. PMID: 40702186 -
Theranostics
The hepatocyte-specifically expressed lnc-HSER alleviates hepatic fibrosis by inhibiting hepatocyte apoptosis and epithelial-mesenchymal transition. [Abstract]2019 Oct 12;9(25):7566-7582. PMID: 31695787 -
J Clin Invest
Neutrophil-microglia interaction drives motor dysfunction in a neuromyelitis optica model induced by subarachnoid AQP4-IgG. [Abstract]2026 Feb 10:e199706. PMID: 41665955 -
Adv Sci (Weinh)
2024 Jun 5:e2400819. PMID: 38837628 -
Cell Death Dis
Intracellular C5aR1 inhibits ferroptosis in glioblastoma through METTL3-dependent m6A methylation of GPX4. [Abstract]2024 Oct 5;15(10):729. PMID: 39368999
PMX 205 Trifluoroacetate purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2024 Oct 5;15(10):729. [Abstract]
Protein expression of GPX4 after treatment with different concentrations of PMX205 (12 h) and the related quantitative analysis.
PMX 205 Trifluoroacetate purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2024 Oct 5;15(10):729. [Abstract]
Representative bioluminescence images acquired by IVIS imaging showing luciferase signals in tumors of mice in the different treatment groups (PMX205: intraperitoneal injection, 5 mg/kg every two days for four weeks) at 1 week, 3 weeks, and 5 weeks.
PMX 205 Trifluoroacetate purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2024 Oct 5;15(10):729. [Abstract]
IHC staining confirmed that PMX205 (intraperitoneal injection, 5 mg/kg every two days for four weeks) induced suppression of GPX4 expression, accumulation of 4-HNE, and inhibition of tumor growth.
PMX 205 Trifluoroacetate purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2024 Oct 5;15(10):729. [Abstract]
PMX205 (intraperitoneal injection, 5 mg/kg every two days for four weeks) induced significant decreases in GPX4 protein expression.
-
Nephrol Dial Transplant
Anti-PLA2R antibodies promote endothelial pyroptosis and a procoagulant phenotype through FcγRI signaling. [Abstract]2026 May 13:gfag109. PMID: 42127088 -
Cell Rep
Physical exercise modulates the microglial complement pathway in mice to relieve cortical circuitry deficits induced by mutant human TDP-43. [Abstract]2023 Mar 15;42(3):112240. PMID: 36924491 -
Cell Mol Neurobiol
Mild Hypothermia Alleviates Complement C5a-Induced Neuronal Autophagy During Brain Ischemia-Reperfusion Injury After Cardiac Arrest. [Abstract]2023 Jul;43(5):1957-1974. PMID: 36006573 -
Mol Neurobiol
The Crosstalk Between Sepsis-Associated Encephalopathy and Alzheimer's Disease: Identifying Potential Biomarkers and Therapeutic Targets for Cognition. [Abstract]2025 Jul 10. PMID: 40634788 -
Int J Cancer
Complement receptor C5aR1 blockade reprograms tumor-associated macrophages and synergizes with anti-PD-1 therapy in gastric cancer. [Abstract]2023 Jul 1;153(1):224-237. PMID: 36799619 -
Clin Immunol
Complement C5a and C5a receptor 1 mediates glomerular damage in focal segmental glomerulosclerosis. [Abstract]2025 Apr:273:110459. PMID: 39984108
PMX 205 Trifluoroacetate purchased from MedChemExpress. Usage Cited in: Clin Immunol. 2025 Apr:273:110459. [Abstract]
C5a (100 ng/ml, 48 h) stimulation increased CD44 expression in PECs at the protein level, effects that were blocked by PMX205 (5, 50, and 500 ng/ml, 48 h) in a dose-dependent manner.
PMX 205 Trifluoroacetate purchased from MedChemExpress. Usage Cited in: Clin Immunol. 2025 Apr:273:110459. [Abstract]
C5a (100 ng/ml, 48 h) stimulation increased CD44 expression in PECs at the mRNA level, effects that were blocked by PMX205 (5, 50, and 500 ng/ml, 48 h) in a dose-dependent manner.
PMX 205 Trifluoroacetate purchased from MedChemExpress. Usage Cited in: Clin Immunol. 2025 Apr:273:110459. [Abstract]
C5a (100 ng/ml, 48 h) exposure increased PEC-derived COL4A2 secretion and mRNA levels. This effect was reversed by PMX205 (5, 50, and 500 ng/ml, 48 h) in a dose-dependent manner.
PMX 205 Trifluoroacetate purchased from MedChemExpress. Usage Cited in: Clin Immunol. 2025 Apr:273:110459. [Abstract]
The proliferation of PECs increased by C5a (100 ng/ml, 48 h) was reduced by PMX205 (5, 50, and 500 ng/ml, 48 h) in a dose-dependent manner.
-
-
bioRxiv
Neutrophil-microglia interaction drives reversible motor dysfunction in neuromyelitis optica model induced by subarachnoid AQP4-IgG. [Abstract]2025 Aug 28:2025.08.22.671883. PMID: 40909582 -
Solvent & Solubility
DMSO : ≥ 100 mg/mL (104.93 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : < 0.1 mg/mL (insoluble)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (2.62 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (2.62 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocol
The mouse mammary tumor cell lines 4T1 are plated at a density 5.0×104 cells/ml/well of 96-multiwell plates in complete medium. After 24 h of incubation, the medium is changed with serum starve medium to synchronize the cell cycle and growth as to ensure that the cells reaches its plateau phase. After 24 h of serum-starving, cells are treated with 5 μL/well of 0.1 M of agonist, EP54, antagonist, PMX 205 and the positive control is treated with Tamoxifen drug. 5 μL/well of the 12 mM ck solution is added 5 h before reading is taken and about 50 μL/well of the SDS-HCL solution is added and mixed thoroughly using pipette 3 h before reading is taken. The MTT assay is assessed at different time point; 0, 24, 48 and 72 h at wavelength 570 nm respectively by using ELISA plate reader Infinite M200[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Rats[2]
Transgenic SOD1G93A rats expressing human mutant G93A SOD1 (NTac:SD-Tg SOD1G93A L26H) are used. Three experimental groups are chosen: untreated, PMX 205 treats from day 28 onward, and PMX 205 treats from day 70 onward. Animals are administered PMX 205 via drinking water (1 mg/kg/day) , from day 28 or day 70 onward; controls receive water only[2].
Mice[3]
Tg2576 mice are treated (starting at or after the initiation of plaque pathology) for 2-3 mo with PMX 205 given in the drinking water only (10-20 μg/mL, equivalent to ~3-6 mg/kg/day) or both in drinking water (10-20 μg/mL) and s.c. (1 mg/kg) twice weekly throughout the treatment period. Untreated transgenic animals of same age are used as controls. Nontransgenic littermates are similarly treated or not treated with the drug. 3×Tg mice are also treated with PMX 205 in the drinking water. Due to the low pathology of the males, only female mice of this strain are used for these studies[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (282 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Kosni NN, et al. Expression of complement C5a receptor and the viability of 4T1 tumor cells following agonist-antagonist treatment. J Cancer Res Ther. 2016 Apr-Jun;12(2):590-6. [Content Brief]
[2]. Woodruff TM, et al. The complement factor C5a contributes to pathology in a rat model of amyotrophic lateral sclerosis. J Immunol. 2008 Dec 15;181(12):8727-34. [Content Brief]
[3]. Fonseca MI, et al. Treatment with a C5aR antagonist decreases pathology and enhances behavioral performance in murine models of Alzheimer's disease. J Immunol. 2009 Jul 15;183(2):1375-83. [Content Brief]
[4]. Toutonji A, et al. Mass cytometric analysis of the immune cell landscape after traumatic brain injury elucidates the role of complement and complement receptors in neurologic outcomes[J]. Acta Neuropathologica Communications, 2023, 11(1): 92. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.0493 mL | 5.2463 mL | 10.4925 mL | 26.2313 mL |
| 5 mM | 0.2099 mL | 1.0493 mL | 2.0985 mL | 5.2463 mL | |
| 10 mM | 0.1049 mL | 0.5246 mL | 1.0493 mL | 2.6231 mL | |
| 15 mM | 0.0700 mL | 0.3498 mL | 0.6995 mL | 1.7488 mL | |
| 20 mM | 0.0525 mL | 0.2623 mL | 0.5246 mL | 1.3116 mL | |
| 25 mM | 0.0420 mL | 0.2099 mL | 0.4197 mL | 1.0493 mL | |
| 30 mM | 0.0350 mL | 0.1749 mL | 0.3498 mL | 0.8744 mL | |
| 40 mM | 0.0262 mL | 0.1312 mL | 0.2623 mL | 0.6558 mL | |
| 50 mM | 0.0210 mL | 0.1049 mL | 0.2099 mL | 0.5246 mL | |
| 60 mM | 0.0175 mL | 0.0874 mL | 0.1749 mL | 0.4372 mL | |
| 80 mM | 0.0131 mL | 0.0656 mL | 0.1312 mL | 0.3279 mL | |
| 100 mM | 0.0105 mL | 0.0525 mL | 0.1049 mL | 0.2623 mL |
PMX 205 Trifluoroacetate Related Classifications
HY-110136A Related Classifications
Powered by Bioz